



Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

February 27, 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 27, 2024-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:

- TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 1:30 PM ET in Boston, MA
- Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 2:40 PM ET in Miami Beach, FL
- Barclays Global Healthcare Conference on Wednesday, March 13, 2024 at 8:00 AM ET in Miami Beach, FL

Live webcasts will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at <https://investors.deciphera.com/events-presentations>. All webcast replays will be archived on the Company's website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera's switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Norway, Singapore, Switzerland, Taiwan, The United Kingdom, and the United States. For more information, visit <https://www.deciphera.com/> and follow us on [LinkedIn](#) and [X](#) (@Deciphera).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240227371221/en/): <https://www.businesswire.com/news/home/20240227371221/en/>

Investor Relations:

Maghan Meyers
Argot Partners
Deciphera@argotpartners.com
212-600-1902

Media:

David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902

Source: Deciphera Pharmaceuticals, Inc.